Faculty

Faculty

Blanca Ledezma

MSN, NP, AOCNP

Department of Hematology Oncology Santa Monica, California

UCLA Health

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Heather McArthur

MD, MPH, FASCO

UT Southwestern Medical Center, Dallas, Texas

Professor, Department of Internal Medicine, Clinical Director, Breast Cancer Program, Komen Distinguished Chair in Clinical Breast Cancer Research

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology and Current Management of Hormone-Receptor (HR)-Positive Metastatic Breast Cancer (mBC); Clinical Relevance of ESR1 Mutations

• Incidence, pathophysiology and clinical characteristics of HR-positive mBC
• Current role of endocrine-based therapies in the management of HR-positive mBC; known mechanisms of resistance to hormonal therapy
• Prevalence of ESR1 mutations in HR-positive, HER2-negative mBC; relevance of prior therapeutic exposure
• Optimal timing and approach to testing for ESR1 mutations in patients with HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating assessment for ESR1 status in patients with HR-positive, HER2-negative mBC and in helping them understand the implications of results

MODULE 2: Current Role of Oral Selective Estrogen Receptor Degraders (SERDs) in Therapy for HR-Positive mBC

• Mechanistic similarities and differences between fulvestrant and the various available and investigational oral SERDs; implications for efficacy and tolerability
• Published efficacy outcomes with elacestrant for patients with progressive HR-positive, HER2-negative mBC
• Major findings documenting the efficacy of imlunestrant monotherapy for patients with pretreated HR-positive, HER2-negative mBC
• FDA approvals of elacestrant and imlunestrant for patients with previously treated HR-positive, HER2-negative mBC and ESR1 mutations
• Identification of patients appropriate for treatment with elacestrant or imlunestrant

MODULE 3: Potential Role of Early Therapeutic Switching from an Aromatase Inhibitor to an Oral SERD After Detection of an Emergent ESR1 Mutation During First-Line Therapy for HR-Positive mBC

• Early-phase data with camizestrant alone for previously treated HR-positive, HER2-negative advanced breast cancer
• Biological rationale for and potential benefit of serial ESR1 testing for patients receiving first-line endocrine therapy
• Design, eligibility criteria and key efficacy and safety findings from the Phase III SERENA-6 study evaluating a switch from an aromatase inhibitor to camizestrant after detection of an emergent ESR1 mutation during first-line therapy for HR-positive, HER2-negative mBC
• Potential role of serial ESR1 testing and early therapeutic switching for patients found to harbor ESR1 mutations

MODULE 4: Potential Role of Combination Approaches with Oral SERDs for HR-Positive, HER2-Negative Breast Cancer

• Biological rationale for combining oral SERDs with other systemic therapies, such as CDK4/6 inhibitors or PI3K/AKT/mTOR inhibitors
• Efficacy and safety outcomes documented with imlunestrant/abemaciclib for patients with HR-positive, HER2-negative advanced breast cancer with and without ESR1 mutations
• Recently presented data comparing giredestrant in combination with everolimus to standard endocrine therapy with everolimus for pretreated HR-positive, HER2-negative mBC
• Potential role of oral SERD-containing combination regimens and identification of patients appropriate for this approach
• Ongoing assessments of other oral SERD-based strategies for patients with HR-positive breast cancer

MODULE 5: Tolerability of Currently Approved and Investigational Oral SERDs

• Spectrum, frequency and severity of common class-effect toxicities, such as gastrointestinal (GI) side effects, musculoskeletal pain, fatigue and myelosuppression, documented with oral SERDs; comparative tolerability of elacestrant and imlunestrant
• Recommended prophylaxis, monitoring and management of GI toxicities associated with oral SERDs
• Pathophysiology of hyperlipidemia observed with elacestrant and imlunestrant; optimal lipid-profile monitoring for patients receiving either agent
• Incidence and severity of anemia and hypocalcemia noted with imlunestrant versus other oral SERDs; appropriate monitoring for and management of laboratory-value abnormalities in patients receiving these agents

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the incidence and clinical implications of ESR1 mutations in endocrine-resistant metastatic breast cancer (mBC), and determine optimal strategies to effectively identify patients harboring these abnormalities.
• Understand the biological rationale for, mechanism of action of and pharmacologic similarities and differences among available and investigational oral selective estrogen receptor degraders (SERDs).
• Interrogate published research documenting the efficacy of oral SERD monotherapy in patients with hormone receptor (HR)-positive, HER2-negative mBC with ESR1 mutations who experience disease progression on standard endocrine therapy in combination with a CDK4/6 inhibitor, in order to optimally understand the role of these agents in patient care.
• Review available research findings with serial ESR1 testing using ctDNA as a means to inform early therapeutic switching for patients with HR-positive mBC receiving CDK4/6 inhibitor-based first-line therapy, and consider the clinical applicability of this novel strategy.
• Evaluate available clinical trial data with oral SERDs in combination with other systemic therapies, such as CDK4/6 inhibitors or mTOR inhibitors, and consider the potential role of these regimens.
• Appreciate side effects associated with available and investigational oral SERDs, and use this information to develop supportive management plans for patients receiving this form of therapy.
• Assess ongoing clinical research evaluating novel applications of oral SERDs for HR-positive breast cancer, and counsel patients regarding the potential benefits of trial participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/OralSERDsMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Ms Ledezma — Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Lilly, Pfizer Inc; Steering Committees: AstraZeneca Pharmaceuticals LP. Dr Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc.

MODERATOR — Dr McArthur — Advisory Committees: Arvinas, AstraZeneca Pharmaceuticals LP, Boston Scientific Corporation, Celcuity, Daiichi Sankyo Inc, Delcath Systems Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Merck, Novartis, Pfizer Inc; Consulting Agreements: ALX Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP, Lilly, and Stemline Therapeutics Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Faculty

Marissa Marti-Smith

DNP, APRN, AGNP-C, AOCNP

Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, Texas

Nurse Practitioner

Faculty

Ruth M O'Regan, MD

University of Rochester Medical Center, Rochester, New York

Charles A Dewey Professor of Medicine and Oncology, Chair, Department of Medicine,

Strong Memorial Hospital, Rochester, New York

Physician-in-Chief

Wilmot Cancer Institute, Rochester, New York

Associate Director of Education and Mentoring

Moderator

Rita Nanda

MD

The University of Chicago, Chicago, Illinois

Director, Breast Oncology, Associate Professor of Medicine, Section of Hematology/Oncology

Program Schedule — Central Time
5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Appropriate Risk Assessment for Patients with Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer; Rationale for the Use of CDK4/6 Inhibitors for Those at High Risk for Recurrence

• Clinicopathologic factors (eg, age, tumor size and grade, nodal involvement) affecting the risk of recurrence for patients with HR-positive, HER2-negative localized breast cancer
• Long-term outcomes achieved with standard adjuvant endocrine therapy with or without chemotherapy for patients with HR-positive, HER2-negative localized breast cancer, including those at high risk for recurrence
• Mechanism of antitumor activity of CDK4/6 inhibitors; similarities and differences among available agents in this class
• Rationale for the addition of CDK4/6 inhibitors to standard adjuvant endocrine therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer

MODULE 2: Role of Adjuvant CDK4/6 Inhibitor Therapy for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer

• Extended follow-up, including recently published overall survival outcomes, with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with high-risk, HR-positive, HER2-negative localized breast cancer
• Five-year outcomes with ribociclib and endocrine therapy compared to endocrine therapy alone as adjuvant treatment for high-risk, HR-positive, HER2-negative localized breast cancer
• FDA-approved indications and identification of appropriate candidates for adjuvant abemaciclib and ribociclib

MODULE 3: CDK4/6 Inhibitors for HR-Positive Metastatic Breast Cancer (mBC)

• Long-term follow-up data with abemaciclib, palbociclib and ribociclib for patients with HR-positive mBC
• Factors affecting the selection of a CDK4/6 inhibitor and an endocrine partner for premenopausal and postmenopausal patients
• Role of CDK4/6 inhibitors in treatment for unique patient populations, such as those with aggressive visceral disease and those with CNS metastases
• Available data on the utility of continuing CDK4/6 inhibitors beyond progression or rechallenge in later lines of therapy; current role of this strategy in clinical practice

MODULE 4: Cytopenias Associated with CDK4/6 Inhibitors

• Similarities and differences in the tolerability profiles of abemaciclib, palbociclib and ribociclib; spectrum and frequency of commonly occurring class-effect toxicities, such as cytopenias, gastrointestinal (GI) events and fatigue
• Appropriate monitoring of complete blood counts during CDK4/6 inhibitor therapy
• Thresholds for dose modification, treatment interruption and treatment discontinuation for patients experiencing cytopenias on CDK4/6 inhibitor therapy

MODULE 5: GI Adverse Events Documented with CDK4/6 Inhibitors

• Rates of various GI issues (eg, diarrhea, nausea and vomiting, constipation, abdominal pain) in patients receiving CDK4/6 inhibitor therapy
• Indications for antidiarrheals and/or antiemetics for patients receiving CDK4/6 inhibitors
• Role of nutritional counselling and diet modifications in CDK4/6 inhibitor treatment

MODULE 6: Rarer but Potentially Serious Toxicities Associated with 1 or More CDK4/6 Inhibitors

• Incidence of interstitial lung disease/pneumonitis associated with CDK4/6 inhibitor therapy; recommended algorithms for monitoring, mitigation and management
• Frequency and severity of hepatotoxicity documented with CDK4/6 inhibitors; appropriate monitoring of liver function tests before and during treatment
• Rates of venous thromboembolic events (VTE) reported with CDK4/6 inhibitor therapy; optimal monitoring for signs of VTE and precautionary measures for patients with preexisting risk factors
• Severe cutaneous adverse reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms) documented with CDK4/6 inhibitors; role of dermatologic consultation in the care of patients with signs or symptoms
• Incidence of cardiac toxicity with ribociclib; appropriate use of electrocardiogram monitoring before and during therapy

MODULE 7: Practical Considerations with CDK4/6 Inhibitors

• Optimal dosing and dose-adjustment strategies with CDK4/6 inhibitors for patients with localized and metastatic breast cancer
• Recommended duration of CDK4/6 inhibitor therapy in the adjuvant setting
• Approaches for encouraging and assessing adherence for patients receiving CDK4/6 inhibitor therapy
• Drug-drug interactions noted with 1 or more CDK4/6 inhibitors

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Discern the mechanism by which the cyclin-dependent kinase (CDK) pathway contributes to breast cancer proliferation and growth, and consider the implications for the management of hormone receptor (HR)-positive disease.
• Understand how various clinical and biological factors, such as age or menopausal status, tumor size or grade and nodal involvement, affect the risk of disease recurrence, and use this information to personalize the selection of adjuvant systemic therapy for patients with newly diagnosed HR-positive, HER2-negative localized breast cancer.
• Consider available clinical trial findings with CDK4/6 inhibitors for localized HR-positive, HER2-negative breast cancer, and identify patients for whom adjuvant treatment with one of these agents would be appropriate.
• Appraise published findings from randomized clinical trials establishing the efficacy and safety of CDK4/6 inhibitors in patients with HR-positive metastatic breast cancer in order to understand the risks, benefits and optimal clinical use of these agents in various patient subgroups.
• Recognize adverse events and other common side effects associated with different CDK4/6 inhibitors for breast cancer, and tailor therapy for patients with preexisting medical conditions and relevant comorbidities.
• Develop preventive and emergent strategies to reduce or ameliorate the various toxicities associated with CDK4/6 inhibitors.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/CDKiHRPositiveBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Marti-Smith — Consulting Agreements: Amplity; Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Daiichi Sankyo Inc, Stemline Therapeutics Inc; Nonrelevant Financial Relationships: ASCO Quality Care Symposium, Clinical Care Options, Kaplan, OncLive, Oncology Nursing News. Dr O’Regan — Advisory Committees: Biotheranostics Inc, A Hologic Company; Consulting Agreements: Biotheranostics Inc, A Hologic Company, Gilead Sciences Inc, Lilly, Puma Biotechnology Inc, Regor Pharmaceuticals; Contracted Research: Novartis, Puma Biotechnology Inc; Data and Safety Monitoring Board/Committee: Gilead Sciences Inc.

MODERATOR — Dr Nanda — Advisory Committees: AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Daiichi Sankyo Inc, Exact Sciences Corporation, Gilead Sciences Inc, Lilly, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Summit Therapeutics; Contracted Research: Arvinas, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Jazz Pharmaceuticals Inc, Mabwell Therapeutics Inc, Merck, Pfizer Inc, Relay Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Lilly and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Beth Faiman

PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio

Adult Nurse Practitioner, Department of Hematology and Medical Oncology

Case Comprehensive Cancer Center, Cleveland, Ohio

Member, Population and Cancer Prevention Program

Faculty

Hans Lee

MD

Sarah Cannon Research Institute, Nashville, Tennessee

Director, Multiple Myeloma Research

Faculty

Mary Steinbach

PhD-c, DNP, FNP-C, APRN

Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah

Lead Ambulatory Advanced Practice Clinician, Division of Hematology

Moderator

Natalie S Callander

MD

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

Professor of Medicine, Director, Myeloma Clinical and Cellular Therapy Program

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)

• Rationale for targeting B-cell maturation antigen (BCMA) with CAR T-cell therapy for MM
• Research database documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for heavily pretreated MM
• Available data with and FDA approvals of ide-cel and cilta-cel in earlier settings; overall survival (OS) advantage documented with cilta-cel
• Identification of appropriate candidates for BCMA-targeted CAR T-cell therapy and optimal sequencing of this strategy opposite other evidence-based approaches
• Early data with and ongoing evaluation of CAR T-cell platforms with targets beyond BCMA (eg, the GPRC5D-directed agent arlocabtagene autoleucel)

MODULE 2: Tolerability and Other Practical Considerations with CAR T-Cell Therapy

• Overview of the CAR T-cell manufacturing and delivery processes
• Incidence, timing and signs and symptoms of cytokine release syndrome (CRS), neurotoxicity or immune effector cell-associated neurotoxicity syndrome (ICANS) and other acute adverse events (AEs) with CAR T-cell therapy; optimal patient monitoring after infusion
• Guideline-endorsed approaches for mitigation and management of CRS, neurotoxicity/ICANS and other AEs with CAR T-cell therapy; role of corticosteroids, tocilizumab and other supportive care interventions
• Educating patients about practical requirements after CAR T-cell infusion (eg, the need to remain within proximity of the treatment center, recommendations regarding driving); implications of the recent elimination of the Risk Evaluation and Mitigation Strategy program for CAR T-cell therapy
• Potential for long-term tolerability/toxicity concerns (eg, delayed neurotoxicity, prolonged cytopenias, hypogammaglobulinemia, infections, secondary malignancies) with CAR T-cell therapy

MODULE 3: Role of B-Cell Maturation Antigen (BCMA)- and Non-BCMA-Targeted Bispecific Antibodies for MM

• Mechanistic similarities and differences between bispecific antibodies and CAR T-cell therapy; targets of various approved bispecific antibodies (eg, teclistamab, elranatamab, linvoseltamab, talquetamab)
• Long-term outcomes observed in pivotal trials of the BCMA-targeted bispecific antibodies teclistamab and elranatamab for heavily pretreated MM
• Efficacy and safety data leading to the FDA approval of the anti-BCMA bispecific antibody linvoseltamab for R/R MM
• Available efficacy and safety data with the non-BCMA-targeted bispecific antibody talquetamab for heavily pretreated disease
• Optimal selection of candidates with R/R MM for BCMA- and non-BCMA-targeted bispecific antibodies; considerations guiding the sequencing of these agents relative to other strategies and each other

MODULE 4: Toxicities and Practical Issues Related to Bispecific Antibodies

• Potential practical advantages of the “off-the-shelf” nature of bispecific antibodies
• Routes of administration, recommended dosing schedules and premedications with the various bispecific antibody platforms for MM; duration of hospitalization during step-up dosing
• Comparative tolerability of BCMA- and non-BCMA-directed bispecific antibodies for MM
• Incidence, severity and time course of CRS and neurotoxicity with bispecific antibodies; recommended protocols for mitigation and management
• Spectrum, frequency and management of other toxicities (eg, hepatotoxicity, infections, neutropenia, skin- and nail-related AEs, oral toxicities) reported with one or more bispecific antibodies

MODULE 5: Utility of Belantamab Mafodotin for R/R MM

• Mechanism of action and structural components of the BCMA-directed antibody-drug conjugate belantamab mafodotin
• Historical efficacy and safety findings with belantamab mafodotin monotherapy for patients with R/R MM; rationale for the withdrawal of this agent
• Key findings with belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone for patients who have received ≥1 prior line of therapy; OS advantage documented with the former combination
• Ongoing FDA review of belantamab mafodotin-based combination strategies; potential clinical role for R/R MM

MODULE 6: Tolerability Considerations with Belantamab Mafodotin

• Pathophysiology and symptomatology of the ocular AEs observed with belantamab mafodotin; impact of dosing on frequency and severity of ocular AEs
• Indications for and timing of ophthalmologic referral for patients about to receive belantamab mafodotin
• Optimal approaches to the management of ocular toxicities with belantamab mafodotin
• Spectrum, frequency, severity and management of other common and uncommon toxicities reported with belantamab mafodotin

MODULE 7: Potential Role of Cereblon E3 Ligase Modulators (CELMoDs) for MM

• Mechanism of action of the CELMoDs iberdomide and mezigdomide; similarities and differences between CELMoDs and standard immunomodulatory agents (IMiDs)
• Published efficacy and safety findings with iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for pretreated MM
• Rationale for the use of minimal residual disease (MRD) negativity as a clinical trial endpoint for MM; emerging Phase III data indicating an improvement in MRD negativity rates with iberdomide/daratumumab/dexamethasone versus daratumumab/bortezomib/dexamethasone for R/R MM
• Other ongoing studies evaluating CELMoD-containing therapy for newly diagnosed and R/R MM; potential clinical role of CELMoDs

MODULE 8: Tolerability/Toxicity Considerations with CELMoDs for MM

• Comparative tolerability profiles of iberdomide, mezigdomide and traditional IMiDs
• Spectrum, frequency and severity of hematologic AEs observed with CELMoDs in published clinical studies
• Incidence and time course of nonhematologic complications (eg, gastrointestinal toxicities, cutaneous AEs, fatigue, infections, peripheral neuropathy) reported with CELMoDs
• Toxicity and tolerability of iberdomide and mezigdomide in combination with other effective antimyeloma therapies; strategies to discern the effects of each individual agent
• Appropriate monitoring, mitigation and management protocols for hematologic and nonhematologic side effects with CELMoDs

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Consider published research findings and other clinical factors that affect the best-practice selection, sequencing and combining of established agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
• Evaluate the biological rationale for chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) as a targeted therapeutic strategy in MM, and discuss with patients when and if this novel strategy should be considered.
• Educate patients with R/R MM about the mechanism of action of, available data with and current clinical role of BCMA- and non-BCMA-directed bispecific antibodies.
• Review recently presented clinical research findings establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy, and recognize the potential clinical role of this form of treatment.
• Appreciate the mechanism of action of, unique characteristics of and available and emerging data with the various cereblon E3 ligase modulators under development, to prepare for their potential clinical availability for patients with R/R MM.
• Implement a plan of care to recognize and manage side effects and toxicities associated with commonly used, recently approved and promising emerging systemic therapies for MM.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/RRMultipleMyeloma/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Faiman — Advisory Committees and Consulting Agreements: Janssen Biotech Inc, Sanofi. Dr Lee — Consulting Agreements (Paid to Institution): AbbVie Inc, Alexion Pharmaceuticals, Allogene Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Legend Biotech, Medline, Pfizer Inc, Predicta Biosciences, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Consulting Agreements (Paid to Self): Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: AbbVie Inc, Alexion Pharmaceuticals, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Moderna, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Steinbach — Advisory Committees: Bristol Myers Squibb, Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc; Contracted Research and Speakers Bureaus: Johnson & Johnson, Pfizer Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Callander has no relevant financial relationships to disclose.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Farrukh T Awan

MD

University of Texas Southwestern Medical Center, Dallas, Texas

Professor of Internal Medicine, Associate Director, Section of Hematologic Malignancies/Transplantation and Cellular Therapies, Director of Lymphoid Malignancies Program, Harold C Simmons Comprehensive Cancer Center

Faculty

Robin Klebig

MSN, APRN, CNP, AOCNP

Mayo Clinic, Rochester, Minnesota

Hematology Outpatient APP Supervisor, Assistant Professor of Medicine, Nurse Practitioner, Lymphoma Group, Division of Hematology

Faculty

Mollie Moran

APRN-CNP, AOCNP

The James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, Ohio

Nurse Practitioner

Moderator

Brad S Kahl

MD

Washington University School of Medicine, St Louis, Missouri

Professor of Medicine

Siteman Cancer Center, St Louis, Missouri

Director, Lymphoma Program

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting

MODULE 1: Current Role of CD20 x CD3 Bispecific Antibodies in the Management of Non-Hodgkin Lymphoma (NHL)

• Design of bispecific antibodies to engage 2 disease targets with 1 molecule; potential therapeutic advantages over traditional monoclonal antibodies
• Scientific rationale for the selection of CD20 and CD3 as targets for bispecific antibodies in NHL; mechanism of antitumor activity
• Pharmacological similarities and differences among the various approved (eg, glofitamab, epcoritamab, mosunetuzumab) and investigational (eg, odronextamab) CD20 x CD3 bispecific antibodies for NHL; implications for efficacy, tolerability and ease of use
• Similarities and differences between bispecific antibodies and chimeric antigen receptor T-cell therapy
• FDA-approved indications for mosunetuzumab, glofitamab and epcoritamab; optimal selection and sequencing of bispecific antibodies for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

MODULE 2: Tolerability Concerns with Bispecific Antibodies for NHL

• Pathophysiology of the CRS and neurotoxicity observed with bispecific antibody therapy, including immune effector cell-associated neurotoxicity syndrome (ICANS)
• Comparative incidence and severity of CRS with bispecific antibodies available for various NHL subtypes
• Common signs and symptoms and typical course of CRS
• Clinical presentation of neurotoxicity/ICANS and common symptoms, such as delirium, dysphasia, lethargy, difficulty concentrating and confusion
• Guideline-endorsed approaches for monitoring, mitigation and management of CRS and neurotoxicity; role of corticosteroids, tocilizumab and other supportive care interventions
• Spectrum, frequency and severity of other common tolerability concerns, such as cytopenia, infections, fatigue, rash, musculoskeletal pain and gastrointestinal (GI) adverse events (AEs), with bispecific antibodies for patients with NHL

MODULE 3: Role of Polatuzumab Vedotin in Therapy for DLBCL

• Structural components of polatuzumab vedotin and mechanism of antitumor activity
• Extended follow-up with polatuzumab vedotin/R-CHP (rituximab, cyclophosphamide, doxorubicin and prednisone) for previously untreated DLBCL
• Current role of polatuzumab vedotin as a component of up-front therapy for DLBCL; appropriate selection of candidates for this strategy
• Efficacy and safety findings with polatuzumab vedotin in combination with chemoimmunotherapy (bendamustine/rituximab, rituximab/gemcitabine/oxaliplatin) or bispecific antibodies (mosunetuzumab) for patients with relapsed/refractory (R/R) DLBCL; current and potential role of these regimens

MODULE 4: Tolerability Considerations with Polatuzumab Vedotin

• Rates and severity of peripheral neuropathy with polatuzumab vedotin; appropriate use of dose adjustments and other management strategies
• Incidence of cytopenias and infections with polatuzumab vedotin-containing regimens; appropriate monitoring of complete blood counts (CBCs) during therapy
• Spectrum and incidence of GI AEs with polatuzumab vedotin-based therapy; strategies for management
• Differences, if any, in the tolerability of polatuzumab vedotin in the up-front versus the R/R setting; implications for AE monitoring and management

MODULE 5: Optimal Application of Loncastuximab Tesirine for Patients with DLBCL or FL

• Mechanism of action and structural makeup of the anti-CD19 antibody-drug conjugate loncastuximab tesirine
• Long-term findings with loncastuximab tesirine for R/R DLBCL; patient selection and optimal sequencing
• Available data with loncastuximab tesirine in combination with other therapies and for other NHL subtypes
• Recent NCCN guideline inclusion of loncastuximab tesirine/rituximab as a third- or later-line treatment option for FL; optimal incorporation into practice

MODULE 6: Tolerability Considerations with Loncastuximab Tesirine

• Incidence, severity and management of edema and effusions with loncastuximab tesirine
• Rates of myelosuppression and infections with loncastuximab tesirine; appropriate monitoring of CBCs during therapy
• Spectrum of cutaneous reactions documented with loncastuximab tesirine, such as photosensitivity reactions, rash and erythema; recommended strategies for mitigation and management
• Initial dosing and dose-modification strategies with loncastuximab tesirine; recommended premedications, such as dexamethasone and G-CSF, for some or all patients

MODULE 7: Current and Future Role of Covalent and Noncovalent Bruton Tyrosine Kinase (BTK) Inhibitors in the Management of Chronic Lymphocytic Leukemia (CLL)

• Indications for initiating active therapy for patients with previously untreated CLL
• Long-term findings from Phase III studies assessing ibrutinib-, acalabrutinib- and zanubrutinib-based therapy for patients with treatment-naïve and R/R CLL; application in current up-front decision-making
• Comparative antitumor activity of BTK inhibitors alone and in combination with anti-CD20 antibodies in the up-front setting; implications for therapy selection

MODULE 8: Tolerability of Covalent and Noncovalent BTK Inhibitors

• Incidence and severity of cardiac arrhythmias, including atrial fibrillation or flutter, documented with approved covalent BTK inhibitors
• Probability of other cardiovascular toxicities, such as stroke, hypertension and bruising or bleeding events, with covalent BTK inhibitor therapy
• Spectrum and frequency of clinically relevant noncardiovascular toxicities, including cytopenias, infections, headache, dermatologic symptoms, arthralgia/myalgia and GI events, with covalent BTK inhibitors
• Appropriate monitoring for and management of treatment-related cardiovascular and noncardiovascular events in patients receiving covalent BTK inhibitors
• Tolerability of pirtobrutinib relative to available covalent BTK inhibitors
• Incidence and severity of cardiac arrhythmias and other cardiovascular and noncardiovascular toxicities documented with pirtobrutinib
• Appropriate monitoring for and management of treatment-related AEs in patients receiving pirtobrutinib
• Safety profile of pirtobrutinib in the front-line setting

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate available research findings with CD20 x CD3 bispecific antibodies for relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), and counsel patients regarding the risks and benefits of this novel approach.
• Recognize the spectrum, frequency and severity of adverse events, such as cytokine release syndrome, neurotoxicity, infections and cytopenias, associated with CD20 x CD3 bispecific antibodies, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Identify patients with newly diagnosed and R/R DLBCL for whom CD79b-targeted antibody-drug conjugate (ADC) therapy would be appropriate.
• Appraise available research findings with and the current clinical role of CD19-targeted ADCs for patients with R/R DLBCL and FL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with ADCs commonly used in the care of patients with NHL.
• Review the similarities and differences between covalent and noncovalent Bruton tyrosine kinase (BTK) inhibitors, and assess the implications for the efficacy and tolerability of these agents.
• Evaluate available Phase III data demonstrating the efficacy of BTK inhibitors as first-line therapy for CLL, and use this information to counsel patients regarding front-line treatment options.
• Discuss available clinical research demonstrating the efficacy and safety of noncovalent BTK inhibitors for newly diagnosed and R/R CLL, and identify patients appropriate for treatment with these agents.
• Appreciate the scientific rationale for the investigation of combined BTK and Bcl-2 inhibition, and review data with and the current and potential role of this strategy for patients with newly diagnosed and R/R CLL.
• Implement a plan of care to recognize and manage side effects and toxicities associated with BTK inhibitors in the management of CLL.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 2 contact hours is provided by Research To Practice.

This activity is awarded 2 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/NHLandCLL/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Klebig and Ms Moran have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Awan — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, DAVA Oncology, Genmab US Inc, Incyte Corporation, Invivyd, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Miltenyi Biotec, Pierre Fabre; Contracted Research: Actinium Pharmaceuticals Inc, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Boards/Committees: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Caribou Biosciences Inc.

MODERATOR — Dr Kahl — Advisory Committees: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Incyte Corporation, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Contracted Research: BeOne, Roche Laboratories Inc; Data and Safety Monitoring Boards/Committees: BeOne, Bristol Myers Squibb, Roche Laboratories Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Lilly.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Reva Basho

MD

Ellison Medical Institute, Los Angeles, California

Breast Medical Oncology, Chief Medical Officer

Faculty

Kelly Fischer

MSN, FNP-BC

Dana-Farber Cancer Institute, Boston, Massachusetts

Family Nurse Practitioner

Faculty

Melissa Rikal

FNP-BC, AOCNP

Sarah Cannon Research Institute, Nashville, Tennessee

Nurse Practitioner

Moderator

Seth Wander

MD, PhD

Massachusetts General Hospital, Boston, Massachusetts

Director of Precision Medicine, Termeer Center for Targeted Therapies, Director of Translational Research, Breast Oncology Program

Harvard Medical School, Boston, Massachusetts

Assistant Professor of Medicine

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Identification of Appropriate Candidates with Hormone Receptor (HR)-Positive Metastatic Breast Cancer (mBC) for Agents Targeting the PI3K/AKT/mTOR Pathway

• Incidence of relevant biomarkers, including alterations along the PI3K/AKT/mTOR pathway, in HR-positive, HER2-negative mBC
• Clinical characteristics associated with PI3K/AKT/mTOR pathway alterations in HR-positive, HER2-negative mBC
• Optimal methodology for and timing of assessment for alterations along the PI3K/AKT/mTOR pathway for HR-positive, HER2-negative mBC
• Role of oncology nurses in facilitating biomarker testing for HR-positive, HER2-negative mBC and helping patients understand the implications of the results

MODULE 2: Role of Inavolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between inavolisib and earlier-generation PI3K inhibitors (ie, alpelisib); implications for efficacy and tolerability
• Key findings with inavolisib in combination with palbociclib and fulvestrant as first-line therapy for patients with endocrine-resistant, PIK3CA-mutated, HR-positive, HER2-negative mBC
• FDA approval of inavolisib/palbociclib/fulvestrant, and current clinical role for newly diagnosed HR-positive, HER2-negative mBC with a PIK3CA mutation
• Ongoing evaluation of inavolisib for endocrine-sensitive, PIK3CA-mutated, HR-positive, HER2-negative mBC; potential role in this setting

MODULE 3: Adverse Events (AEs) Associated with Inavolisib

• Incidence of hyperglycemia with inavolisib; optimal monitoring of fasting glucose levels and HbA1c
• Appropriate management of hyperglycemia occurring with inavolisib; indications for antidiabetic medications and dose modifications
• Incidence of gastrointestinal (GI) toxicities (eg, diarrhea, stomatitis, nausea) with inavolisib; strategies for mitigation and management
• Spectrum, frequency, severity and management of other toxicities (eg, cytopenias, fatigue, rash) documented with inavolisib-containing therapy

MODULE 4: Clinical Utility of Capivasertib in the Management of HR-Positive mBC

• Biological rationale for inhibiting AKT in the management of HR-positive mBC; mechanism of action of capivasertib
• Key efficacy and safety data with capivasertib/fulvestrant for recurrent HR-positive, HER2-negative mBC
• FDA approval of capivasertib for patients with HR-positive, HER2-negative mBC with PIK3CA/AKT1/PTEN alterations, and current role opposite other evidence-based options
• Ongoing evaluation of the triplet combination of capivasertib, fulvestrant and a CDK4/6 inhibitor as first-line therapy for patients with HR-positive, HER2-negative mBC who experience disease progression on or within 12 months of completing (neo)adjuvant endocrine therapy

MODULE 5: Side Effects and Other Practical Considerations with Capivasertib

• Recommended management strategies for patients experiencing diarrhea and other GI disorders while receiving capivasertib
• Pathophysiology, spectrum and optimal treatment of cutaneous adverse reactions with capivasertib
• Incidence of hyperglycemia in patients receiving capivasertib; indications for blood glucose monitoring and role, if any, for patients with preexisting diabetes
• Dose, schedule and recommended approach to dose modifications with capivasertib

MODULE 6: Potential Role of Gedatolisib in the Management of HR-Positive mBC

• Mechanistic similarities and differences between gedatolisib and currently approved therapies targeting the PI3K/AKT/mTOR pathway for HR-positive mBC; implications for antitumor activity
• Recently presented data from the PIK3CA wild-type cohort of a Phase III study evaluating gedatolisib in combination with fulvestrant with or without palbociclib for patients with HR-positive, HER2-negative mBC whose disease progressed on or after prior CDK4/6 inhibitor therapy and an aromatase inhibitor
• Anticipated read-out of the PIK3CA-mutated cohort of the aforementioned study
• Potential role of gedatolisib-containing combination therapy for pretreated HR-positive, HER2-negative mBC that is PIK3CA wild type and PIK3CA mutated

MODULE 7: Tolerability Profile of Gedatolisib

• Rates of treatment discontinuation due to an AE documented with gedatolisib/palbociclib/fulvestrant and gedatolisib/fulvestrant
• Incidence and severity of hyperglycemia and diarrhea with gedatolisib-based therapy relative to other agents targeting the PI3K/AKT/mTOR pathway
• Spectrum and incidence of other treatment-related AEs documented with gedatolisib-based therapy (eg, stomatitis, neutropenia, nausea, vomiting, rash, fatigue)
• Strategies to monitor for, mitigate and manage treatment-related AEs with gedatolisib

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of breast cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Review available research documenting the correlation between various biomarkers, such as PIK3CA/AKT1/PTEN alterations and ESR1 mutations, and response to specific therapies, and understand optimal testing algorithms for patients with hormone receptor (HR)-positive metastatic breast cancer (mBC).
• Recognize the frequency of PIK3CA/AKT/PTEN alterations in HR-positive mBC, and educate patients with newly diagnosed and relapsed/refractory disease about evidence-based approaches to targeting these aberrations.
• Understand the biological rationale for the development of agents targeting multiple components of the PI3K/AKT/mTOR pathway, and recognize available and emerging data with this strategy for patients with HR-positive, PIK3CA wild-type and PIK3CA-mutant mBC.
• Assess the spectrum, frequency and severity of adverse events associated with available and emerging agents targeting the PI3K/AKT/mTOR pathway, and consider recommended approaches to prevent, ameliorate and manage these side effects.
• Evaluate available research findings with and ongoing studies evaluating novel PI3K/AKT/mTOR inhibitor-based approaches, and consider the potential role of these strategies.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PI3KAKTmTORMetastaticBreastCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Fischer has no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Basho — Advisory Committees: AstraZeneca Pharmaceuticals LP, Celcuity, Novartis, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celcuity, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Pfizer Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Scorpion Therapeutics; Data and Safety Monitoring Boards/Committees: Pfizer Inc; Speakers Bureaus: DAVA Oncology, MDOutlook; Nonrelevant Financial Relationships: Community Health Media, OncLive, Targeted Oncology. Ms Rikal — Advisory Committees: Stemline Therapeutics Inc; Consulting Agreements and Speakers Bureaus: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. Additional faculty to be announced.

MODERATOR — Dr Wander — Consulting Agreements: Arvinas, AstraZeneca Pharmaceuticals LP, Biotheranostics Inc, A Hologic Company, Biovica International AB, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, Lilly, Menarini Group, Novartis, Pfizer Inc, Puma Biotechnology Inc, Regor Therapeutics, Stemline Therapeutics Inc, Veracyte Inc; Contracted Research: Arvinas, Genentech, a member of the Roche Group, Lilly, Menarini Group, Nuvation Bio Inc, Pfizer Inc, Phoenix Molecular Designs, Puma Biotechnology Inc, Regor Therapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Celcuity, and Genentech, a member of the Roche Group.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Caroline Kuhlman

MSN, APRN-BC

Massachusetts General Brigham Cancer Institute, Boston, Massachusetts

Nurse Practitioner, Tucker Gosnell Center for Gastrointestinal Cancers

Faculty

Philip A Philip

MD, PhD

Wayne State University Department of Oncology, Detroit, Michigan

Chair, Hematology and Oncology, Professor of Oncology and Pharmacology, Co-Leader, Pancreatic Cancer Program, Medical Director, Cancer Clinical and Translational Research Office, Chair, GI Cancer, SWOG, Henry Ford Cancer Institute

Faculty

Amanda K Wagner

APRN-CNP, AOCNP

The James Cancer Hospital, The Ohio State University, Columbus, Ohio

GI Malignancies

Moderator

Eileen M O’Reilly

MD

David M Rubenstein Center for Pancreatic Cancer Research, New York, New York

Winthrop Rockefeller Endowed Chair in Medical Oncology, Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers, Co-Director, Medical Initiatives

Memorial Sloan Kettering Cancer Center, New York, New York

Chair, Human Research Protection Program and IRB, Attending Physician, Member

Weill Cornell Medical College, New York, New York

Professor of Medicine

Program Schedule — Central Time

5:30 AM – 6:00 AM — Registration and Dinner
6:00 AM – 7:30 AM — Educational Meeting

MODULE 1: Clinical Presentation and Prognosis of Pancreatic Adenocarcinoma (PAD)

• Risk factors for the development of pancreatic cancer, such as family history/ genetic predisposition syndromes, smoking, obesity/diet and metabolic diseases
• Rationale for the high proportion of PAD cases diagnosed in the advanced stages of the disease
• Factors contributing to the aggressive nature of PAD; prognosis associated with advanced disease
• Common presenting symptoms of PAD, such as asthenia, anorexia/weight loss, pain and jaundice
• Importance of palliative care for patients with advanced PAD

MODULE 2: Recent Advances in Up-Front Treatment for Metastatic PAD

• Impact of age, performance status, comorbidities, patient preferences and prior (neo)adjuvant therapy, if any, on the choice of first-line treatment for metastatic PAD
• Historical data establishing the efficacy and safety of FOLFIRINOX and gemcitabine/nab paclitaxel for patients with previously untreated advanced PAD
• Proposed mechanism of improved delivery of cytotoxic therapy to pancreatic cancer cells with nanoliposomal irinotecan (nal-IRI) compared to conventional chemotherapy
• Key efficacy and safety outcomes reported with nal-IRI, fluorouracil (5-FU)/leucovorin (LV) and oxaliplatin (NALIRIFOX) versus gemcitabine/nab paclitaxel for previously untreated metastatic PAD
• FDA approval of up-front NALIRIFOX for patients with metastatic PAD; selection of optimal candidates for this regimen

MODULE 3: Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Metastatic PAD

• Key factors influencing the selection and sequencing of available therapies for R/R metastatic PAD
• Long-term efficacy and safety findings with nal-IRI in combination with 5-FU/LV after disease progression on gemcitabine-based therapy
• Patient selection for and practical integration of nal-IRI in the R/R setting
• Other evidence-based chemotherapeutic agents or regimens for patients with progressive metastatic PAD

MODULE 4: Tolerability and Other Practical Considerations with Nanoliposomal Irinotecan (Nal-IRI) and Other Cytotoxic Approaches

• Comparative tolerability/toxicity profile of NALIRIFOX and other commonly employed first-line regimens, such as FOLFIRINOX and gemcitabine/nab paclitaxel
• Rates of diarrhea and other gastrointestinal (GI) issues documented with nal-IRI; indications for prophylactic antidiarrheals and antiemetics for patients who are about to start treatment
• Incidence and severity of cytopenias with nal-IRI; role of growth factor use and appropriate monitoring of complete blood counts during therapy
• Recommended dosing of nal-IRI as part of the first-line NALIRIFOX regimen versus in the R/R setting
• Effect of dose adjustment on the efficacy of first-line NALIRIFOX; implications for the feasibility of tolerability-guided dosing strategies

MODULE 5: Novel Strategies Targeting RAS Mutations in Advanced PAD

• Incidence and spectrum of RAS mutations in PAD; impact on patient outcomes
• Mechanism of antitumor activity of the RAS(ON) multiselective inhibitor daraxonrasib and rationale for its investigation in advanced PAD
• Early efficacy outcomes with daraxonrasib as monotherapy and in combination with gemcitabine/nab paclitaxel for patients with previously treated and treatment-naïve advanced PAD harboring RAS mutations
• FDA breakthrough therapy designation for daraxonrasib for previously treated KRAS G12-mutant advanced PAD
• Ongoing and planned Phase III trials of daraxonrasib alone or in combination with chemotherapy for patients with PAD

MODULE 6: Tolerability of RAS-Targeted Therapies Under Investigation for Advanced PAD

• Incidence, time to onset and severity of GI side effects (eg, diarrhea, nausea, vomiting, stomatitis/mucositis, liver enzyme elevations) with daraxonrasib for patients with PAD
• Spectrum, incidence and severity of daraxonrasib-associated dermatologic issues, including rash, dry skin, paronychia and others
• Strategies to mitigate, monitor for and manage potential treatment-emergent adverse events (AEs) with daraxonrasib should it become available
• Impact on the tolerability of daraxonrasib when combined with chemotherapy

MODULE 7: Potential Utility of Tumor Treating Fields (TTFields) in the Management of PAD

• Mechanism of action of TTFields and biological rationale for their investigation in PAD
• Antitumor activity reported with TTFields in combination with gemcitabine and nab paclitaxel as first-line treatment for unresectable, locally advanced PAD
• Recent FDA approval of TTFields for locally advanced PAD; integration into clinical algorithms
• Ongoing evaluation of TTFields in combination with atezolizumab, gemcitabine and nab paclitaxel as first-line treatment for metastatic PAD

MODULE 8: Tolerability and Other Practical Considerations with TTFields

• Components of the TTFields system; placement of arrays for patients with PAD
• Appropriate skin preparation prior to array placement and during array changes with TTFields
• Spectrum, incidence and severity of dermatologic AEs documented with TTFields; appropriate mitigation and management strategies
• Other practical considerations associated with TTFields use, such as appropriate duration of treatment per day, bathing procedures and ability to travel

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of pancreatic cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appreciate the biological, clinical and logistical factors that affect the selection of first-line therapy for locally advanced or metastatic pancreatic adenocarcinoma (PAD), and incorporate this information into patient education discussions.
• Assess published efficacy findings with regimens incorporating novel chemotherapeutic formulations as first-line therapy for patients with metastatic PAD, and understand the current role of these approaches.
• Examine available datasets exploring the effect of dose adjustments on the efficacy of chemotherapeutic regimens employed in the management of newly diagnosed metastatic PAD, and consider the potential feasibility of tolerability-guided dosing strategies.
• Recognize FDA-approved treatment approaches for metastatic PAD that has progressed on front-line chemotherapy, and counsel patients regarding the risks and benefits of these strategies.
• Evaluate the mechanism of action of, published research findings with and potential clinical role of tumor treating fields for unresectable, locally advanced PAD.
• Recall relevant oncogenic pathways mediating the pathogenesis of PAD, and discern the implications for biomarker analysis and treatment decision-making.
• Appreciate the spectrum and frequency of RAS mutations found in patients with metastatic PAD, and develop an understanding of available data with and ongoing research studies of novel agents designed to exploit this emerging therapeutic pathway.
• Design and implement a plan of care to recognize and manage side effects and toxicities associated with approved systemic regimens commonly employed in the management of PAD, to support quality of life and continuation of therapy.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/PancreaticCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Kuhlman and Ms Wagner have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Philip — Advisory Committees: Corcept Therapeutics Inc, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Novocure Inc, Revolution Medicines Inc; Consulting Agreements: Novocure Inc; Contracted Research: Bristol Myers Squibb, Novartis, Revolution Medicines Inc, Taiho Oncology Inc; Data and Safety Monitoring Board/Committees: J-Pharma Co Ltd, Oncolytics Biotech Inc.

MODERATOR — Dr O’Reilly — Advisory Committees and Consulting Agreements (Uncompensated): Agenus Inc, Alligator Bioscience, Amgen Inc, Arcus Biosciences, Astellas, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Ikena Oncology, Immuneering Corporation, Ipsen Biopharmaceuticals Inc, Merck, MOMA Therapeutics, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Tango Therapeutics; Contracted Research: Agenus Inc, Amgen Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Revolution Medicines Inc, Tango Therapeutics; Nonrelevant Financial Relationships: American Association of Cancer Research (Editor), American Society of Clinical Oncology (Editor), Break Through Cancer, Imedex, National Cancer Institute (Cancer Center Support Grant/Core Grant), National Institutes of Health (research grant), Stand Up 2 Cancer.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Ipsen Biopharmaceuticals Inc and Revolution Medicines Inc.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Alexandra Drakaki

University of California, Los Angeles, Los Angeles, California

Associate Professor of Medicine, Hematology/Oncology and Urology, Medical Director of the Genitourinary Oncology Program, Leader of the Genitourinary Research Program

Faculty

Krisztina Emodi

NP-C, MPH, CNS

UCSF Helen Diller Family Comprehensive Cancer Center San Francisco, California

GU Surgical Oncology

Faculty

Margarita Huober

MS, AGNP-C, AOCNP

Stanford Health Care, Palo Alto, California

Nurse Practitioner, Genitourinary Medical Oncology

Moderator

Terence Friedlander

MD

Zuckerberg San Francisco General Hospital, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California

Professor of Medicine and Robert and Virginia O’Reilly Family Endowed Chair, Chief, Division of Hematology/Oncology

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Immune Checkpoint Inhibitors in Non-Muscle-Invasive Bladder Cancer (NMIBC)

• Current management algorithms for NMIBC; key findings informing the selection of patients with bacillus Calmette-Guérin (BCG)-unresponsive NMIBC for pembrolizumab therapy
• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with BCG for BCG-naïve, high-risk NMIBC
• Available efficacy and safety data with durvalumab and sasanlimab, respectively, in combination with BCG for BCG-naïve, high-risk NMIBC
• Potential role of anti-PD-1/PD-L1 antibodies with BCG for BCG-naïve, high-risk NMIBC

MODULE 2: Perioperative Systemic Therapy for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer (MIBC)

• Rationale for the evaluation of anti-PD-1/PD-L1 antibodies administered perioperatively for MIBC
• Key efficacy and safety findings documented with neoadjuvant durvalumab in combination with gemcitabine/cisplatin followed by radical cystectomy and adjuvant durvalumab monotherapy for MIBC
• FDA approval of durvalumab as a component of perioperative systemic therapy for MIBC
• Selection of appropriate candidates with MIBC for perioperative durvalumab therapy; role, if any, for patients with preexisting autoimmune conditions, compromised renal function, et cetera

MODULE 3: Evolving Approach to Systemic Therapy for Cisplatin-Ineligible Patients with MIBC

• Pathophysiology, spectrum, frequency, severity and timing of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies
• Impact on the tolerability of anti-PD-1/PD-L1 antibodies when administered in combination with other therapies (eg, BCG, chemotherapy, enfortumab vedotin)
• Optimal monitoring for immune-related and other potential AEs with immune checkpoint inhibitors; importance of prompt reporting of symptoms
• Recommended algorithms for the management of various immune-related AEs by grade/severity

MODULE 4: Novel Intravesical Therapies for Nonmetastatic UBC

• Advantages of intravesical delivery systems to administer systemic therapies for nonmetastatic UBC
• Available findings with the gemcitabine intravesical system for BCG-unresponsive high-risk NMIBC in patients who are ineligible for or decline radical cystectomy
• FDA approval of the gemcitabine intravesical system for the treatment of BCG-unresponsive NMIBC with carcinoma in situ, with or without papillary tumors; selection of appropriate candidates for this strategy
• Initial safety and efficacy results with the erdafitinib intravesical delivery system TAR-210 for patients with NMIBC and select FGFR alterations
• Ongoing Phase III evaluations of the gemcitabine intravesical system and TAR-210 for nonmetastatic UBC

MODULE 5: Tolerability/Toxicity Profile of and Other Practical Considerations with Novel Intravesical Therapies

• Importance of pretreatment evaluation of bladder integrity for patients about to receive intravesical therapy
• Logistics of insertion and removal of the gemcitabine intravesical system and TAR-210
• Incidence of urinary issues (eg, urinary frequency, urinary tract infection/pain, dysuria, micturition urgency, hematuria) related to the gemcitabine intravesical system; optimal strategies to mitigate these effects
• Spectrum, frequency and severity of systemic toxicities with the gemcitabine intravesical system (eg, myelosuppression, other laboratory abnormalities, pneumonia); appropriate monitoring and management protocols
• Incidence, severity and management of local and systemic side effects noted with TAR-210

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this approach.
• Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
• Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
• Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
• Assess the biological basis for and recently presented research data with combined perioperative anti-PD-1 antibody and antibody-drug conjugate therapy for patients with MIBC and consider the current and potential clinical role of this approach.
• Analyze the scientific justification for perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this strategy.
• Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/BladderCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures will be provided.

FACULTY — Ms Emodi and Ms Huober have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Drakaki — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; Contracted Research: Acrivon Therapeutics, Adcentrx Therapeutics, Allogene Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Infinity Pharmaceuticals Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Nektar Therapeutics; Speakers Bureaus: AstraZeneca Pharmaceuticals LP; Stock OPTIONS — Private Companies: Athos Therapeutics; Nonrelevant Financial Relationships: Dyania Health.

MODERATOR — Dr Friedlander — Advisory Committees: Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; Consulting Agreements: Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; Contracted Research: AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Michael Lai

MSN, ARNP, FNP-C

University of Washington School of Medicine Seattle, Washington

Advanced Practice Provider Fred Hutchinson Cancer Center Teaching Associate

Faculty

Stacy E Walker

FNP-BC

Harvard Medical School Boston, Massachusetts

Nurse Practitioner Dana-Farber Cancer Institute

Faculty

Evan Y Yu

MD

Fred Hutchinson Cancer Center, Seattle, Washington

Section Head, Medical Oncology, Clinical Research Division

Fred Hutchinson Cancer Research Consortium, Seattle, Washington

Medical Director, Clinical Research Support

University of Washington School of Medicine, Seattle, Washington

Professor of Medicine, Division of Hematology and Oncology, Department of Medicine

Moderator

Scott T Tagawa

MD, MS

Weill Cornell Medicine, New York, New York

Professor of Medicine and Urology

Meyer Cancer Center, New York, New York

Leader, GU Disease Management Team

Program Schedule — Central Time

11:45 AM – 12:15 PM — Registration and Lunch
12:15 PM – 1:45 PM — Educational Meeting

MODULE 1: Hormonal Therapy for Nonmetastatic Hormone-Sensitive Prostate Cancer (nmHSPC)

• Rationale for the evaluation of treatment intensification with androgen receptor (AR) pathway inhibitors for patients with nmHSPC
• Key findings, including overall survival outcomes, with enzalutamide combined with leuprolide versus enzalutamide or leuprolide alone for men with nmHSPC and high-risk biochemical recurrence after definitive therapy
• FDA approval and optimal application of enzalutamide with and without androgen deprivation therapy (ADT) for nmHSPC
• Published data with ADT intensification with apalutamide with or without abiraterone for patients with high-risk biochemically recurrent nmHSPC

MODULE 2: Hormonal Therapy for Metastatic HSPC (mHSPC)

• Extended follow-up with abiraterone, enzalutamide and apalutamide in combination with ADT for men with mHSPC
• Published data with the addition of darolutamide to ADT for patients with mHSPC; recent FDA approval of this regimen
• Clinical factors guiding the selection of a specific secondary hormonal agent for patients with mHSPC; available datasets exploring the relative benefit of the various approved therapies in this setting
• Published efficacy and safety data with darolutamide in combination with docetaxel and ADT for mHSPC; selection of optimal candidates for triplet therapy

MODULE 3: Tolerability of Hormonal Therapy for Prostate Cancer

• Incidence of hypertension and other cardiovascular (CV) adverse events (AEs) with different hormonal agents; optimal pretreatment assessment, on-therapy monitoring and management of CV events
• Spectrum and frequency of central nervous system-related AEs (eg, seizures, cognitive decline, falls, fatigue) observed with hormonal therapy for patients with prostate cancer
• Prevalence, mitigation and management of other notable side effects (eg, fractures, hot flashes, sarcopenias) with available hormonal therapies for prostate cancer
• Tolerability profile of enzalutamide with and without ADT for nmHSPC; differences, if any, in the experience with this agent in later settings

MODULE 4: Potential Role of Capivasertib in the Management of mHSPC

• Frequency of PTEN deficiency in patients with prostate cancer; optimal approach to assessment of PTEN status
• Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease; mechanism of action of capivasertib
• Recently presented efficacy and safety results with the addition of capivasertib to abiraterone/ADT for patients with de novo mHSPC and PTEN deficiency
• Potential integration of capivasertib/abiraterone/ADT into treatment algorithms

MODULE 5: Tolerability Profile of Capivasertib

• Recommended side-effect management strategies for patients experiencing diarrhea and other gastrointestinal (GI) disorders while receiving capivasertib
• Incidence of hyperglycemia among patients receiving capivasertib; appropriate glucose monitoring and interventions for those with elevated blood glucose levels
• Optimal mitigation and management of cutaneous adverse reactions associated with capivasertib
• Appropriate monitoring of complete blood counts for patients receiving capivasertib; recommended dose modifications for those experiencing cytopenias

MODULE 6: Current and Future Role of PARP Inhibitors in Therapy for Metastatic Prostate Cancer

• Incidence and clinical implications of BRCA1/2 and other homologous recombination repair (HRR) abnormalities in prostate cancer; recommended timing and optimal method for genetic testing
• Biological basis for combining PARP inhibitors with secondary hormonal therapies in metastatic prostate cancer
• Long-term efficacy and safety findings with olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide as first-line therapy for patients with metastatic castration-resistant prostate cancer (mCRPC)
• FDA-approved indications for olaparib/abiraterone, niraparib/abiraterone and talazoparib/enzalutamide in mCRPC; optimal selection of patients for these approaches
• Recently presented data with the addition of niraparib to abiraterone/prednisone for patients with mHSPC harboring alterations in HRR genes; clinical implications and integration into treatment algorithms
• Other ongoing Phase III efforts evaluating combined PARP/AR pathway inhibition in this setting

MODULE 7: Tolerability of PARP Inhibitors Used for Prostate Cancer

• Incidence, timing and severity of common class-effect and agent-specific toxicities associated with PARP inhibitors for patients with metastatic prostate cancer
• Optimal monitoring and management strategies for PARP inhibitor-related toxicities
• Impact on the tolerability of PARP inhibitors when administered in combination with secondary hormonal therapy
• Strategies for identifying the root cause of toxicities in patients receiving PARP inhibitor/secondary hormonal therapy combinations that may be attributable to either agent

MODULE 8: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Prostate Cancer

• Clinical relevance of PSMA expression in prostate cancer; mechanism of action of lutetium Lu 177 vipivotide tetraxetan
• Published datasets with lutetium Lu 177 vipivotide tetraxetan for patients with taxane-naïve and taxane-pretreated PSMA-positive mCRPC
• Appropriate sequencing of lutetium Lu 177 vipivotide tetraxetan with regard to other available therapies for mCRPC
• Recently presented data with the addition of lutetium Lu 177 vipivotide tetraxetan to hormonal therapy for patients with PSMA-positive mHSPC; implications for clinical practice

MODULE 9: Current and Future Role of Lutetium Lu 177 Vipivotide Tetraxetan in Treatment for Metastatic Prostate Cancer

• Incidence, severity and management of commonly occurring AEs with radium-223 (eg, cytopenias, GI toxicity, peripheral edema, fractures)
• Recommended algorithms for the management of common AEs observed in patients receiving lutetium Lu 177 vipivotide tetraxetan (eg, fatigue, dry mouth, GI toxicity, cytopenias)
• Educating patients receiving radiopharmaceuticals regarding radiation risks and appropriate protection precautions
• Other practical considerations related to the administration of novel radiopharmaceuticals for prostate cancer (eg, locating and referring patients to a nuclear medicine treatment center)

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Appraise published research findings on optimal management approaches for patients with biochemical recurrence following local treatment for prostate cancer, and counsel appropriate individuals regarding the potential benefits of FDA-approved systemic treatment options.
• Evaluate the published research supporting the FDA approvals of secondary hormonal agents for nonmetastatic prostate cancer, and apply this information to educate patients about personalized treatment recommendations.
• Explore available data with treatment intensification with cytotoxic therapy, secondary hormonal therapy or combinations of these approaches for metastatic hormone-sensitive prostate cancer (mHSPC), and identify patients for these strategies.
• Assess the available research supporting PARP inhibitors in combination with androgen receptor pathway inhibitors for patients with metastatic prostate cancer harboring a homologous recombination repair gene alteration, and discern how to optimally incorporate these agents into current clinical management algorithms.
• Appreciate the biological rationale for targeting the PI3K/AKT/mTOR pathway for prostate cancer, and evaluate available data with novel AKT inhibitors in combination with hormonal therapy for patients with mHSPC and PTEN deficiency.
• Review available Phase III data documenting the efficacy of various forms of radioligand therapy for metastatic prostate cancer, and consider the current and future clinical role of these strategies.
• Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/ProstateCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Mr Lai and Ms Walker have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Yu — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Johnson & Johnson, Lantheus, Merck, Novartis, Samsung Bioepis, Tolmar; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Pfizer Inc, Tyra Biosciences Inc. 

MODERATOR
Dr Tagawa — Consulting Agreements: AbbVie Inc, Abdera Therapeutics, Bayer HealthCare Pharmaceuticals, Biohaven, Blue Earth Diagnostics, Boston Scientific Corporation, Clarity Pharmaceuticals, Convergent Therapeutics Inc, Daiichi Sankyo Inc, EMD Serono Inc, GE Healthcare, Gilead Sciences Inc, Johnson & Johnson, Lantheus, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Telix Pharmaceuticals Limited; Contracted Research: AIQ Solutions, Bayer HealthCare Pharmaceuticals, Clarity Pharmaceuticals, Gilead Sciences Inc, Janux Therapeutics, Johnson & Johnson, Lilly, Merck, Novartis, Pfizer Inc, Telix Pharmaceuticals Limited; Data and Safety Monitoring Boards/Committees: Boston Scientific Corporation; Stock OPTIONS — Private Companies: Convergent Therapeutics.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Merck, and Novartis.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.

Faculty

Faculty

Sarah Karpen

MPAS, PA-C

Moores Cancer Center, University of California San Diego Health, San Diego, California

APP Supervisor Medical Oncology, Division of Gynecologic Oncology

Faculty

J Alejandro Rauh-Hain

MD, MPH

The University of Texas MD Anderson Cancer Center Houston, Texas

Associate Professor, Tenure Track Deputy Division Head for Clinical Research, Division of Surgery Dept of Gynecologic Oncology and Reproductive Medicine Dept of Health Services Research

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

Moderator

Dana M Chase

MD

David Geffen School of Medicine at UCLA, Los Angeles, California

Professor, Division of Gynecologic Oncology

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

• Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
• Similarities and differences among the currently available anti-PD-1/PD-L1 antibodies for EC, such as dostarlimab, pembrolizumab and durvalumab
• Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
• Frequency of potential biomarkers of response to immune checkpoint inhibitors in EC (eg, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, POLE mutations); optimal approach to biomarker assessment for patients with newly diagnosed disease

MODULE 2: First-Line Therapy for Advanced or Recurrent EC

• Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
• Impact of MSI/MMR status on outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
• FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
• Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

MODULE 3: Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

• Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
• Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by dostarlimab/niraparib maintenance compared to carboplatin/paclitaxel alone in advanced or recurrent EC
• Published efficacy and safety results with durvalumab in combination with chemotherapy followed by durvalumab and olaparib maintenance for patients with newly diagnosed advanced or recurrent EC
• Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

MODULE 4: Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

• Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies in advanced EC
• Recommended monitoring and management approaches for immune-related and other AEs with immune checkpoint inhibitors
• Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic partners (eg, chemotherapy, PARP inhibitors) when these agents are administered in combination
• Role of rechallenge in treatment for patients for whom immune checkpoint inhibitor therapy has been held due to immune-mediated toxicity
• Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

MODULE 5: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

• Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
• Long-term findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC with disease progression after prior systemic therapy
• Optimal integration of lenvatinib/pembrolizumab into EC management algorithms
• Utility of lenvatinib/pembrolizumab among patients who have experienced disease progression on up-front chemoimmunotherapy

MODULE 6: Toxicities with Lenvatinib/Pembrolizumab

• Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab (eg, hypertension, gastrointestinal issues, weight loss, hand-foot syndrome)
• Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
• Initial dosing and dose-modification strategies for lenvatinib/pembrolizumab in EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
• Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab among patients receiving the combination

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

• Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC).
• Appreciate available clinical research findings with the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
• Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
• Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
• Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents/regimens.
• Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Shaver and Dr Rauh-Hain have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Karpen — Speakers Bureaus: Amgen Inc.

MODERATOR — Dr Chase — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; Consulting Agreements: AbbVie Inc, GSK; Contracted Research: GSK, Merck; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; Nonrelevant Financial Relationships: NRG Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.